

Approved



**Namibia**  
**Country Operational Plan**  
**FY 2017**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		157,299		157,299	482,412	639,711
USAID		32,533,444		32,533,444	0	32,533,444
PC		0		0	1,266,000	1,266,000
HHS/CDC	1,487,500	31,973,345		33,460,845	0	33,460,845
HHS/HRSA		300,000		300,000	0	300,000
State/AF		100,000		100,000	0	100,000
<b>Total</b>	<b>1,487,500</b>	<b>65,064,088</b>	<b>0</b>	<b>66,551,588</b>	<b>1,748,412</b>	<b>68,300,000</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/AF	USAID		
CIRC			2,387,804	0			1,593,171	0	3,980,975
HBHC			1,032,759	0	0		1,484,998	0	2,517,757
HKID					0		4,454,141	0	4,454,141
HLAB		0	930,291					0	930,291
HTXS			12,764,757	300,000		100,000	10,050,228	0	23,214,985
HVAB			0				1,600,000	0	1,600,000
HVCT			2,021,851	0			1,617,862	0	3,639,713
HVMS	157,299	0	2,816,143		0		2,288,149	0	5,261,591
HVOP			2,426,042		0	0	3,224,283	0	5,650,325
HVSI		0	1,702,485	0			2,116,609	0	3,819,094
HVTB			1,659,426	0			2,001,081	0	3,660,507

Approved



MTCT		0	1,552,928	0			251,489	0	<b>1,804,417</b>
OHSS		0	1,457,096	0			537,941	0	<b>1,995,037</b>
PDCS			582,207	0			604,653	0	<b>1,186,860</b>
PDTX			2,127,056	0		0	708,839	0	<b>2,835,895</b>
	<b>157,299</b>	<b>0</b>	<b>33,460,845</b>	<b>300,000</b>	<b>0</b>	<b>100,000</b>	<b>32,533,444</b>	<b>0</b>	<b>66,551,588</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	2,121,696	0
HKID	4,384,601	0
HVTB	2,899,600	0
PDCS	723,184	0
<b>Total Technical Area Planned Funding:</b>	<b>10,129,081</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	772,889	0
HVSI	3,001,138	0
OHSS	1,737,675	0
<b>Total Technical Area Planned Funding:</b>	<b>5,511,702</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	3,909,170	0
HVAB	1,600,000	0
HVCT	3,205,060	0
HVOP	5,555,042	0
MTCT	1,388,200	0
<b>Total Technical Area Planned Funding:</b>	<b>15,657,472</b>	<b>0</b>

Approved



**Technical Area: Treatment**

<b>Budget Code</b>	<b>Budget Code Planned Amount</b>	<b>On Hold Amount</b>
HTXS	19,657,948	0
PDTX	1,816,233	0
<b>Total Technical Area Planned Funding:</b>	<b>21,474,181</b>	<b>0</b>



### Technical Area Summary Indicators and Targets

Indicator Number	Label	2019
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	42,749
	Number of new ANC and L&D clients	
	By Age (Denominator): Unknown Age	14,311
	By Age (Denominator): <10	0
	By Age (Denominator): 10-14	0
	By Age (Denominator): <15-19	5,484
	By Age (Denominator): 20-24	9,215
	By Age (Denominator): 25-49	15,870
	By Age (Denominator): 50+	0
	By Number of known positives: Unknown Age	1,675
	By Number of known positives: <10	0
	By Number of known positives: 10-14	0
	By Number of known positives: 15-19	475
	By Number of known positives: 20-24	1,020
By Number of known positives:	2,449	



	25-49	
	By Number of known positives: 50+	0
	By Number of new positives: Unknown Age	644
	By Number of new positives: <10	0
	By Number of new positives: 10-14	0
	By Number of new positives: 15-19	166
	By Number of new positives: 20-24	418
	By Number of new positives: 25-49	777
	By Number of new positives: 50+	0
	By Number of new negative: Unknown Age	11,254
	By Number of new negative: <10	0
	By Number of new negative: 10-14	0
	By Number of new negative: 15-19	4,375
	By Number of new negative: 20-24	7,161
	By Number of new negative: 25-49	12,341
	By Number of new negative: 50+	0
	By Age (Numerator): Unknown Age	0
	By Age (Numerator): <10	0
	By Age (Numerator): 10-14	0
	By Age (Numerator): 15-19	4,988
	By Age (Numerator): 20-24	8,556
	By Age (Numerator): 25-49	15,521
	By Age (Numerator): 50+	0
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and	16,755



	received their results)	
	Number of new ANC and L&D clients	
	By Age (Denominator): Unknown Age	
	By Age (Denominator): <10	0
	By Age (Denominator): 10-14	0
	By Age (Denominator): 15-19	2,933
	By Age (Denominator): 20-24	5,370
	By Age (Denominator): 25-49	9,016
	By Age (Denominator): 50+	0
	By known positives: <Unknown Age	
	By known positives: <10	0
	By known positives: 10-14	0
	By known positives: 15-19	52
	By known positives: 20-24	168
	By known positives: 25-49	1,716
	By known positives: 50+	0
	By new positives: Unknown Age	
	By new positives: <10	0
	By new positives: 10-14	0
	By new positives: 15-19	111
	By new positives: 20-24	218
	By new positives: 25-49	476
	By new positives: 50+	0
	By new negatives: Unknown Age	
	By new negatives: <10	0
	By new negatives: 10-14	0
	By new negatives: 15-19	2,365
	By new negatives: 20-24	4,245
	By new negatives: 25-49	6,972





	By new negatives: 50+	0
	By Age (Numerator): Unknown Age	
	By Age (Numerator): <10	0
	By Age (Numerator): 10-14	0
	By Age (Numerator): : 15-19	2,617
	By Age (Numerator): 20-24	4,726
	By Age (Numerator): 25-49	9,206
	By Age (Numerator): 50+	0
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	17 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	7,189
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	42,749
	New on ART	2,091
	Already on ART at beginning of current pregnancy	5,098
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	16 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission	2,658



	(MTCT) during pregnancy	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,755
	New on ART	658
	Already on ART at beginning of current pregnancy	2,000
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	43,603
	By Age: 0-60 days	
	By Age: 2 months - 9 years	
	By Age: 10-14	6,009
	By Age: 15-19	15,852
	By Age: 20-24	12,576
	By Age: 25-29	7,396
	By Age: 30-49	1,770
	By Age: 50+	
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	43,603
By circumcision technique:		



	Device-based VMMC	
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement	
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,550
	Male 10-14	
	Male 15-19	57
	Male 20-24	155
	Male 25-49	239
	Male 50+	81
	Female 10-14	
	Female 15-19	77
	Female 20-24	321
	Female 25-49	445
	Female 50+	175
	(15-19)	
	(20-24)	
	FSW	325



	MSM	115
	TG	
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	163,387
	Total number of people in the target population	
	Age/sex: 10-14 Male	3,055
	Age/sex: 15-19 Male	10,791
	Age/sex: 20-24 Male	13,716
	Age/sex: 25-49 Male	16,021
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	6,785
	Age/sex: 15-19 Female	22,109
	Age/sex: 20-24 Female	36,748
	Age/sex: 25-49 Female	32,254
	Age/sex: 50+ Female	
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	
	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the	n/a



	minimum standards required (DSD)	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	13,208
	Total estimated number of key population in the catchment area	
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,729
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of	



	<p>key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>9,479</p>
	<p>By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the</p>	



	minimum standards required)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	



	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: Returning beneficiary within the current report period	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	103,766
	By Test Result: Positive	7,691
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 10-14,	





	Female, Positive	
	Service Delivery Point (Community) Homebased testing: 10-14, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 10-14, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	
	Service Delivery Point (Community)	



	Homebased testing: 25-49, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 50+, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 50+, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Homebased testing: <1, Negative	
	Service Delivery Point (Community)	



	Homebased testing: <1, Positive	
	Service Delivery Point (Community) Homebased testing: 1-9, Negative	
	Service Delivery Point (Community) Homebased testing: 1-9, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: <15, Female, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: <15, Female, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: <15, Male, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: <15, Male, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: 15+, Female, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: 15+, Female, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: 15+, Male, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: 15+, Male, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: Unknown Age, Female, Positive	



	Service Delivery Point Agg Age (Community) Homebased testing: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	



	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Inpatient: <1, Negative	
	Service Delivery Point (Facility) Inpatient: <1, Positive	
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	
	Service Delivery Point Agg Age (Facility) Inpatient: <15, Female,	64



	Negative	
	Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Positive	13
	Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Negative	61
	Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Positive	6
	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Negative	759
	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Positive	121
	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Negative	393
	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Positive	56
	Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	
	Service Delivery Point (Facility)	5



	Malnutrition: Negative	
	Service Delivery Point (Facility) Malnutrition: Positive	1
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 20-24, Male,	



	Negative	
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: Unknown Age,	





	Male, Negative	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: <1, Negative	
	Service Delivery Point (Community) Mobile Testing: <1, Positive	
	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	
	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: <15, Female, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: <15, Female, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: <15, Male, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: <15, Male, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Female, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Female, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Male, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Male, Positive	



	Male, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 20-24, Female,	



	Negative	
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male,	



	Negative	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Other PITC: <1, Negative	
	Service Delivery Point (Facility) Other PITC: <1, Positive	
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	
	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Negative	4,030
	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Positive	147
	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Negative	2,387
	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Positive	119
	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	37,526
	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive	3,056
	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	25,576
	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male,	1,769



	Positive	
	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Other: 10-14, Female, Negative	
	Service Delivery Point (Community) Other: 10-14, Female, Positive	
	Service Delivery Point (Community) Other: 10-14, Male, Negative	
	Service Delivery Point (Community) Other: 10-14, Male, Positive	
	Service Delivery Point (Community) Other: 15-19, Female, Negative	
	Service Delivery Point (Community) Other: 15-19, Female, Positive	
	Service Delivery Point (Community) Other: 15-19, Male, Negative	
	Service Delivery Point (Community) Other: 15-19, Male, Positive	
	Service Delivery Point (Community) Other: 20-24, Female, Negative	
	Service Delivery Point (Community) Other: 20-24, Female, Positive	
	Service Delivery Point (Community)	



	Other: 20-24, Male, Negative	
	Service Delivery Point (Community) Other: 20-24, Male, Positive	
	Service Delivery Point (Community) Other: 25-49, Female, Negative	
	Service Delivery Point (Community) Other: 25-49, Female, Positive	
	Service Delivery Point (Community) Other: 25-49, Male, Negative	
	Service Delivery Point (Community) Other: 25-49, Male, Positive	
	Service Delivery Point (Community) Other: 50+, Female, Negative	
	Service Delivery Point (Community) Other: 50+, Female, Positive	
	Service Delivery Point (Community) Other: 50+, Male, Negative	
	Service Delivery Point (Community) Other: 50+, Male, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Other: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Other: <1, Negative	
	Service Delivery Point (Community)	



	Other: <1, Positive	
	Service Delivery Point (Community) Other: 1-9, Negative	
	Service Delivery Point (Community) Other: 1-9, Positive	
	Service Delivery Point Agg Age (Community) Other: <15, Female, Negative	
	Service Delivery Point Agg Age (Community) Other: <15, Female, Positive	
	Service Delivery Point Agg Age (Community) Other: <15, Male, Negative	
	Service Delivery Point Agg Age (Community) Other: <15, Male, Positive	
	Service Delivery Point Agg Age (Community) Other: 15+, Female, Negative	
	Service Delivery Point Agg Age (Community) Other: 15+, Female, Positive	
	Service Delivery Point Agg Age (Community) Other: 15+, Male, Negative	
	Service Delivery Point Agg Age (Community) Other: 15+, Male, Positive	
	Service Delivery Point Agg Age (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Community) Other: Unknown Age, Female, Positive	



	Service Delivery Point Agg Age (Community) Other: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Community) Other: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Pediatric : <5 Negative	159
	Service Delivery Point (Facility) Pediatric : <5 Positive	3
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	





	Service Delivery Point (Facility) TB: 25-49, Female, Negative	
	Service Delivery Point (Facility) TB: 25-49, Female, Positive	
	Service Delivery Point (Facility) TB: 25-49, Male, Negative	
	Service Delivery Point (Facility) TB: 25-49, Male, Positive	
	Service Delivery Point (Facility) TB: 50+, Female, Negative	
	Service Delivery Point (Facility) TB: 50+, Female, Positive	
	Service Delivery Point (Facility) TB: 50+, Male, Negative	
	Service Delivery Point (Facility) TB: 50+, Male, Positive	
	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) TB: <1, Negative	
	Service Delivery Point (Facility) TB: <1, Positive	
	Service Delivery Point (Facility) TB: 1-9, Negative	
	Service Delivery Point (Facility) TB: 1-9, Positive	
	Service Delivery Point Agg Age (Facility) TB: <15, Female,	7



	Negative	
	Service Delivery Point Agg Age (Facility) TB: <15, Female, Positive	0
	Service Delivery Point Agg Age (Facility) TB: <15, Male, Negative	8
	Service Delivery Point Agg Age (Facility) TB: <15, Male, Positive	0
	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Negative	106
	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Positive	19
	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Negative	115
	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Positive	20
	Service Delivery Point Agg Age (Facility) TB: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) TB: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) TB: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) TB: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) VMC: <1, Negative	
	Service Delivery Point (Facility) VMC: <1, Positive	
	Service Delivery Point (Facility) VMC: 10-14, Negative	



	Service Delivery Point (Facility) VMMC: 10-14, Positive	
	Service Delivery Point (Facility) VMMC: 15-19, Negative	
	Service Delivery Point (Facility) VMMC: 15-19, Positive	
	Service Delivery Point (Facility) VMMC: 1-9, Negative	
	Service Delivery Point (Facility) VMMC:	
	Service Delivery Point (Facility) VMMC: 20-24, Negative	
	Service Delivery Point (Facility) VMMC: 20-24, Positive	
	Service Delivery Point (Facility) VMMC: 25-49, Negative	
	Service Delivery Point (Facility) VMMC: 25-49, Positive	
	Service Delivery Point (Facility) VMMC: 50+, Negative	
	Service Delivery Point (Facility) VMMC: 50+, Positive	
	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	
	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	
	Service Delivery Point Agg Age (Facility) VMMC: <15, Negative	182
	Service Delivery Point Agg Age (Facility) VMMC: <15, Positive	0
	Service Delivery Point Agg Age (Facility) VMMC: 15+, Negative	2,771
	Service Delivery Point Agg Age (Facility) VMMC: 15+, Positive	209



	Service Delivery Point Agg Age (Facility) VMMC: Unknown Age, Negative	
	Service Delivery Point Agg Age (Facility) VMMC: Unknown Age, Positive	
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	
	Service Delivery Point (Facility) Index: 20-24, Male, Negative	
	Service Delivery Point (Facility) Index: 20-24, Male, Positive	
	Service Delivery Point (Facility) Index: 25-49, Female, Negative	
	Service Delivery Point (Facility) Index: 25-49, Female, Positive	



	Service Delivery Point (Facility) Index: 25-49, Male, Negative	
	Service Delivery Point (Facility) Index: 25-49, Male, Positive	
	Service Delivery Point (Facility) Index: 50+, Female, Negative	
	Service Delivery Point (Facility) Index: 50+, Female, Positive	
	Service Delivery Point (Facility) Index: 50+, Male, Negative	
	Service Delivery Point (Facility) Index: 50+, Male, Positive	
	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Index: <1, Negative	
	Service Delivery Point (Facility) Index: <1, Positive	
	Service Delivery Point (Facility) Index: 1-9, Negative	
	Service Delivery Point (Facility) Index: 1-9, Positive	
	Service Delivery Point Agg Age (Facility) Index: <15, Female,	0



	Negative	
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	0
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	0
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	0
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	3,712
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	388
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	2,170
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	260
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	
	By Key Population: FSW, Negative	
	By Key Population: FSW, Positive	



	By Key Population: MSM, Negative	
	By Key Population: MSM, Positive	
	By Key Population: People in prisons and other enclosed settings, Negative	
	By Key Population: People in prisons and other enclosed settings, Positive	
	By Key Population: PWID, Negative	
	By Key Population: PWID, Positive	
	By Key Population: TG, Negative	
	By Key Population: TG, Positive	
	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	
	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	
	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	
	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	



	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	
	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	
	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	
	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	
	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	
	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Index Mod: Unknown Age, Male,	





	Positive	
	Service Delivery Point (Community) Index Mod: <1, Negative	
	Service Delivery Point (Community) Index Mod: <1, Positive	
	Service Delivery Point (Community) Index Mod: 1-9, Negative	
	Service Delivery Point (Community) Index Mod: 1-9, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: <15, Female, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: <15, Female, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: <15, Male, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: <15, Male, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: 15+, Female, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: 15+, Female, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: 15+, Male, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: 15+, Male, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: Unknown	



	Age, Female, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) ANC: <1, Negative	
	Service Delivery Point (Facility) ANC: <1, Positive	
	Service Delivery Point (Facility) ANC: 10-14, Negative	
	Service Delivery Point (Facility) ANC: 10-14, Positive	
	Service Delivery Point (Facility) ANC: 15-19, Negative	
	Service Delivery Point (Facility) ANC: 15-19, Positive	
	Service Delivery Point (Facility) ANC: 1-9, Negative	
	Service Delivery Point (Facility) ANC: 1-9, Positive	
	Service Delivery Point (Facility) ANC: 20-24, Negative	
	Service Delivery Point (Facility) ANC: 20-24, Positive	
	Service Delivery Point (Facility) ANC: 25-49, Negative	
	Service Delivery Point (Facility) ANC: 25-49, Positive	



	Service Delivery Point (Facility) ANC: 50+, Negative	
	Service Delivery Point (Facility) ANC: 50+, Positive	
	Service Delivery Point (Facility) ANC: Unknown Age, Negative	
	Service Delivery Point (Facility) ANC: Unknown Age, Positive	
	Service Delivery Point Agg Age (Facility) ANC: <15, Negative	
	Service Delivery Point Agg Age (Facility) ANC: <15, Positive	
	Service Delivery Point Agg Age (Facility) ANC: 15+, Negative	12,139
	Service Delivery Point Agg Age (Facility) ANC: 15+, Positive	852
	Service Delivery Point Agg Age (Facility) ANC: Unknown Age, Negative	
	Service Delivery Point Agg Age (Facility) ANC: Unknown Age, Positive	
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	



	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	
	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	
	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	
	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	
	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	



	Service Delivery Point (Facility) VCT: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) VCT: <1, Negative	
	Service Delivery Point (Facility) VCT: <1, Positive	
	Service Delivery Point (Facility) VCT: 1-9, Negative	
	Service Delivery Point (Facility) VCT: 1-9, Positive	
	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Negative	
	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Positive	
	Service Delivery Point Agg Age (Facility) VCT: <15, Male, Negative	
	Service Delivery Point Agg Age (Facility) VCT: <15, Male, Positive	
	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	
	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive	
	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	
	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive	
	Service Delivery Point Agg Age	



	(Facility) VCT: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) VCT: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) VCT: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) VCT: Unknown Age, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	
	Service Delivery Point (Community)	



	VCT Mod: 20-24, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community) VCT Mod: <1, Negative	
	Service Delivery Point (Community) VCT Mod: <1, Positive	
	Service Delivery Point (Community)	



	VCT Mod: 1-9, Negative	
	Service Delivery Point (Community) VCT Mod: 1-9, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: <15, Female, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: <15, Female, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: <15, Male, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: <15, Male, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: 15+, Female, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: 15+, Female, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: 15+, Male, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: 15+, Male, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown	





	Age, Male, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown	
	Age, Male, Positive	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	87 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,907
	Total number of registered new and relapsed TB cases, during the reporting period.	6,805
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator:	



	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and	



	relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	101
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,405
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	98
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	918
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	



	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	



	cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	127
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,475
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	116
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	950
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	96 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,343
	Total number of registered new and relapsed TB cases, during the reporting period.	2,437
	Aggregated Age/Sex: Female <15 (Denominator: Total number of	48



	registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	21
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	189
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	169
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with	



	documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	18
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	165
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	46
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	183
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: Total number of	





	registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
HTC_TST_DSD	Number of individuals who received	289,059



	T&C services for HIV and received their test results during the past 12 months	
	By Test Result: Positive	23,497
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 10-14, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 10-14, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	
	Service Delivery Point (Community)	



	Homebased testing: 20-24, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 50+, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 50+, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Positive	



	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Homebased testing: <1, Negative	
	Service Delivery Point (Community) Homebased testing: <1, Positive	
	Service Delivery Point (Community) Homebased testing: 1-9, Negative	
	Service Delivery Point (Community) Homebased testing: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative	510
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive	28
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative	350
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive	17
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative	16,659
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive	1,611
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Negative	12,936



Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Positive	1,187
Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Female, Negative	
Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Female, Positive	
Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Male, Negative	
Service Delivery Point by Agg Age (Community) by Aggregated Age: Homebased testing: Unknown Age, Male, Positive	
Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	42
Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	5
Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	47
Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	5
Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	576
Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	30
Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	193
Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	10
Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	753



	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	118
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,247
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	150
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	



	Service Delivery Point (Facility) Inpatient: <1, Negative	
	Service Delivery Point (Facility) Inpatient: <1, Positive	
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	450
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	57
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	800
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	101
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	10,700
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	857
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	5,615
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	660
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	0



	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	0
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	0
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	0
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 20-24, Female,	





	Negative	
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: Unknown Age,	



	Female, Negative	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: <1, Negative	
	Service Delivery Point (Community) Mobile Testing: <1, Positive	
	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	
	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	3,031
	Service Delivery Point by Agg Age(Community) Mobile Testing:	241



	15+, Female, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	1,631
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	125
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,645
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	83
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	887
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	43
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	634
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	31



	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	341
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	11
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	3,961
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	214
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,134
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	121
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	
	Service Delivery Point (Facility) Other PITC: Unknown Age,	



	Female, Negative	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	
	Service Delivery Point (Facility)Other PITC: <1, Negative	
	Service Delivery Point (Facility) Other PITC: <1, Positive	
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	4,910
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	270
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	3,838
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	282
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	56,539
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female,	4,679



	Positive	
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	28,272
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	2,283
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	0
	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	0
	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	
	Service Delivery Point (Community) Other: 10-14, Female, Positive	
	Service Delivery Point (Community) Other: 10-14, Male, Negative	
	Service Delivery Point (Community) Other: 10-14, Male, Positive	
	Service Delivery Point (Community) Other: 15-19, Female, Negative	
	Service Delivery Point (Community) Other: 15-19, Female, Positive	
	Service Delivery Point (Community) Other: 15-19, Male, Negative	



	Service Delivery Point (Community) Other: 15-19, Male, Positive	
	Service Delivery Point (Community) Other: 20-24, Female, Negative	
	Service Delivery Point (Community) Other: 20-24, Female, Positive	
	Service Delivery Point (Community) Other: 20-24, Male, Negative	
	Service Delivery Point (Community) Other: 20-24, Male, Positive	
	Service Delivery Point (Community) Other: 25-49, Female, Negative	
	Service Delivery Point (Community) Other: 25-49, Female, Positive	
	Service Delivery Point (Community) Other: 25-49, Male, Negative	
	Service Delivery Point (Community) Other: 25-49, Male, Positive	
	Service Delivery Point (Community) Other: 50+, Female, Negative	
	Service Delivery Point (Community) Other: 50+, Female, Positive	
	Service Delivery Point (Community) Other: 50+, Male, Negative	
	Service Delivery Point (Community) Other: 50+, Male, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Male,	



	Negative	
	Service Delivery Point (Community) Other: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Other: <1, Negative	
	Service Delivery Point (Community) Other: <1, Positive	
	Service Delivery Point (Community) Other: 1-9, Negative	
	Service Delivery Point (Community) Other: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) Other: <15, Female, Negative	2,371
	Service Delivery Point by Agg Age (Community) Other: <15, Female, Positive	92
	Service Delivery Point by Agg Age (Community) Other: <15, Male, Negative	1,608
	Service Delivery Point by Agg Age (Community) Other: <15, Male, Positive	92
	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	11,324
	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	634
	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	7,311
	Service Delivery Point by Agg Age (Community) Other: 15+, Male,	415





	Positive	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Pediatric : <5 Negative	5,466
	Service Delivery Point (Facility) Pediatric : <5 Positive	170
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	0
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	0
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	7
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	5
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	11
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	8
	Service Delivery Point (Facility) TB:	18



	20-24, Female, Negative	
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	13
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	47
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	35
	Service Delivery Point (Facility) TB: 25-49, Female, Negative	0
	Service Delivery Point (Facility) TB: 25-49, Female, Positive	0
	Service Delivery Point (Facility) TB: 25-49, Male, Negative	0
	Service Delivery Point (Facility) TB: 25-49, Male, Positive	0
	Service Delivery Point (Facility) TB: 50+, Female, Negative	0
	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
	Service Delivery Point (Facility) TB: 50+, Male, Negative	0
	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) TB: <1, Negative	0
	Service Delivery Point (Facility) TB:	0



	<1, Positive	
	Service Delivery Point (Facility) TB: 1-9, Negative	0
	Service Delivery Point (Facility) TB: 1-9, Positive	0
	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	10
	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	0
	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	29
	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	0
	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	571
	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	123
	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	293
	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	124
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	0
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	0
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	0
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male,	0



	Positive	
	Service Delivery Point (Facility) VMMC: <1, Negative	
	Service Delivery Point (Facility) VMMC: <1, Positive	0
	Service Delivery Point (Facility) VMMC: 10-14, Negative	
	Service Delivery Point (Facility) VMMC: 10-14, Positive	0
	Service Delivery Point (Facility) VMMC: 15-19, Negative	300
	Service Delivery Point (Facility) VMMC: 15-19, Positive	2
	Service Delivery Point (Facility) VMMC: 1-9, Negative	
	Service Delivery Point (Facility) VMMC: 1-9, Positive	0
	Service Delivery Point (Facility) VMMC: 20-24, Negative	418
	Service Delivery Point (Facility) VMMC: 20-24, Positive	19
	Service Delivery Point (Facility) VMMC: 25-49, Negative	
	Service Delivery Point (Facility) VMMC: 25-49, Positive	0
	Service Delivery Point (Facility) VMMC: 50+, Negative	
	Service Delivery Point (Facility) VMMC: 50+, Positive	0
	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	
	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	0
	Service Delivery Point (Facility)	224



	VMMC: <15, Negative	
	Service Delivery Point by Agg Age (Facility) VMMC: <15, Positive	7
	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	1,951
	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	67
	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Negative	
	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Positive	
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	5
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	1
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	0
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	0
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	248
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	16
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	151
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	6
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	378
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	85
	Service Delivery Point (Facility)	413



	Index: 20-24, Male, Negative	
	Service Delivery Point (Facility)	90
	Index: 20-24, Male, Positive	
	Service Delivery Point (Facility)	167
	Index: 25-49, Female, Negative	
	Service Delivery Point (Facility)	21
	Index: 25-49, Female, Positive	
	Service Delivery Point (Facility)	92
	Index: 25-49, Male, Negative	
	Service Delivery Point (Facility)	12
	Index: 25-49, Male, Positive	
	Service Delivery Point (Facility)	16
	Index: 50+, Female, Negative	
	Service Delivery Point (Facility)	2
	Index: 50+, Female, Positive	
	Service Delivery Point (Facility)	15
	Index: 50+, Male, Negative	
	Service Delivery Point (Facility)	2
	Index: 50+, Male, Positive	
	Service Delivery Point (Facility)	0
	Index: Unknown Age, Female, Negative	
	Service Delivery Point (Facility)	0
	Index: Unknown Age, Female, Positive	
	Service Delivery Point (Facility)	0
	Index: Unknown Age, Male, Negative	
	Service Delivery Point (Facility)	0
	Index: Unknown Age, Male, Positive	
	Service Delivery Point (Facility)	22
	Index: <1, Negative	
	Service Delivery Point (Facility)	3



	Index: <1, Positive	
	Service Delivery Point (Facility) Index: 1-9, Negative	16
	Service Delivery Point (Facility) Index: 1-9, Positive	2
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	491
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	18
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	506
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	22
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	7,515
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	894
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	5,890
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	884
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	0
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	0
	Service Delivery Point Agg Age (Facility) Index: Unknown Age,	0



	Male, Negative	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	0
	By Key Population: FSW, Negative	
	By Key Population: FSW, Positive	
	By Key Population: MSM, Negative	
	By Key Population: MSM, Positive	
	By Key Population: People in prisons and other enclosed settings, Negative	
	By Key Population: People in prisons and other enclosed settings, Positive	
	By Key Population: PWID, Negative	
	By Key Population: PWID, Positive	
	By Key Population: TG, Negative	
	By Key Population: TG, Positive	
	Service Delivery Point (Facility) Malnutrition: Negative	28
	Service Delivery Point (Facility) Malnutrition: Positive	3
	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	
	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	
	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	
	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	
	Service Delivery Point (Community) Index Mod: 15-19, Female,	





	Negative	
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	
	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	
	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	
	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	
	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	
	Service Delivery Point (Community)	



	Index Mod: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Index Mod: <1, Negative	
	Service Delivery Point (Community) Index Mod: <1, Positive	
	Service Delivery Point (Community) Index Mod: 1-9, Negative	
	Service Delivery Point (Community) Index Mod: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	0
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Positive	0
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Negative	0
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Positive	0
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	10,826
	Service Delivery Point by Agg Age	1,616



	(Community) Index Mod: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	6,888
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	1,065
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) ANC: <1, Negative	
	Service Delivery Point (Facility) ANC: <1, Positive	
	Service Delivery Point (Facility) ANC: 10-14, Negative	
	Service Delivery Point (Facility) ANC: 10-14, Positive	
	Service Delivery Point (Facility) ANC: 15-19, Negative	1,567
	Service Delivery Point (Facility) ANC: 15-19, Positive	30
	Service Delivery Point (Facility) ANC: 1-9, Negative	



	Service Delivery Point (Facility) ANC: 1-9, Positive	
	Service Delivery Point (Facility) ANC: 20-24, Negative	2,764
	Service Delivery Point (Facility) ANC: 20-24, Positive	167
	Service Delivery Point (Facility) ANC: 25-49, Negative	5,198
	Service Delivery Point (Facility) ANC: 25-49, Positive	354
	Service Delivery Point (Facility) ANC: 50+, Negative	
	Service Delivery Point (Facility) ANC: 50+, Positive	
	Service Delivery Point (Facility) ANC: Unknown Age, Negative	
	Service Delivery Point (Facility) ANC: Unknown Age, Positive	
	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	4
	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	0
	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	11,861
	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	1,240
	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	11,256
	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	642
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	



	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	
	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	
	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	
	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	
	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	



	Service Delivery Point (Facility) VCT: 50+, Male, Negative	
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) VCT:	
	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) VCT: <1, Negative	
	Service Delivery Point (Facility) VCT: <1, Positive	
	Service Delivery Point (Facility) VCT: 1-9, Negative	
	Service Delivery Point (Facility) VCT: 1-9, Positive	
	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	777
	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	62
	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	944
	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	95
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female,	13,381



	Negative	
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	1,376
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	5,366
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	555
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	0
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Positive	0
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	0
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Positive	0
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	



	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Male,	





	Negative	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community) VCT Mod: <1, Negative	
	Service Delivery Point (Community) VCT Mod: <1, Positive	
	Service Delivery Point (Community) VCT Mod: 1-9, Negative	
	Service Delivery Point (Community) VCT Mod: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Female, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Male, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male,	



	Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Positive	
GEND_GBV_DSD	Number of people receiving post-GBV care	838
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	401
	By type of service: Sexual Violence (Post-Rape Care)	437
	By PEP service provision (related to sexual violence services provided)	324
	<10, Female, Physical and/or Emotional Violence	
	<10, Female, Sexual Violence (Post-Rape Care)	
	<10, Male, Physical and/or Emotional Violence	
	<10, Male, Sexual Violence (Post-Rape Care)	
	10-14, Female, Physical and/or Emotional Violence	62
	10-14, Female, Sexual Violence	42



	(Post-Rape Care)	
	10-14, Male, Physical and/or Emotional Violence	4
	10-14, Male, Sexual Violence (Post-Rape Care)	
	15-19, Female, Physical and/or Emotional Violence	105
	15-19, Female, Sexual Violence (Post-Rape Care)	139
	15-19, Male, Physical and/or Emotional Violence	20
	15-19, Male, Sexual Violence (Post-Rape Care)	
	20-24, Female, Physical and/or Emotional Violence	170
	20-24, Female, Sexual Violence (Post-Rape Care)	256
	20-24, Male, Physical and/or Emotional Violence	40
	20-24, Male, Sexual Violence (Post-Rape Care)	
	25-49, Female, Physical and/or Emotional Violence	100
	25-49, Female, Sexual Violence (Post-Rape Care)	
	25-49, Male, Physical and/or Emotional Violence	40
	25-49, Male, Sexual Violence (Post-Rape Care)	
	50+, Female, Physical and/or Emotional Violence	
	50+, Female, Sexual Violence (Post-Rape Care)	
	50+, Male, Physical and/or	



	Emotional Violence	
	50+, Male, Sexual Violence (Post-Rape Care)	
	Unknown Age, Female, Physical and/or Emotional Violence	
	Unknown Age, Female, Sexual Violence (Post-Rape Care)	
	Unknown Age, Male, Physical and/or Emotional Violence	
	Unknown Age, Male, Sexual Violence (Post-Rape Care)	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	35,460
	Age/Sex: 10-14 Male	2,416
	Age/Sex: 15-17 Male	2,567
	By: Age/sex: Male 18-24	1,257
	By: Age/sex: Male 25+	222
	Age/Sex: 18+ Male	
	Age/Sex: 10-14 Female	5,738
	Age/Sex: 15-17 Female	12,111
	By: Age/sex: 18-24 Female	5,275
	By: Age/sex: 25+ Female	1,441
	Age/Sex: 18+ Female	
	Sum of Age/Sex disaggregates	22,832
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,408
Required only for DREAMS	2,304	



	countries - By service, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	1,530
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	1,408
	Required only for DREAMS	2,304



	countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	1,530
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS	1,408



	countries - By service, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	2,304
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	1,530
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and	502



	sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	763
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	508
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS	





	countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	443
	Age/Sex: 1-9	3,990
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS	



	countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	28,811
	Program Completion: Graduation	3,990
	Program Completion: Transferred	2,217
	Program Completion: Exited without graduation	442
	By Aggregated Age/Sex: <18 Male	
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and	



	sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	92 %
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,348
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,555
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	



	<p>Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during</p>	



	the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	146
	Aggregated Age/Sex: Male 15+	263



	(Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	63
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	166
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of	



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented	



	HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	167





	treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	291
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	70
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	170
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	91 %
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,037
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	1,143



	period	
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	



	the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator:	



	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The	



	number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented	



	HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	7,198
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	
	By infants who received their first virologic HIV test between 2 and 12 months of age	
	Sum of Infant Age disaggregates	
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	52
	Number of infants with a positive virological test result within 12 months of birth	
	Unknown, <= 2 months	0
	Unknown, 2 - 12 months	0
	Number of infants with a negative virological test result within 2 months of birth	5,466
	Number of infants with a positive virological test result between 2 and 12 months of birth	78
	Number of infants with a negative	1,602





	virological test result between 2 and 12 months of birth	
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,454
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	
	By infants who received their first virologic HIV test between 2 and 12 months of age	
	Sum of Infant Age disaggregates	
	By infants with a positive virologic test result within 12 months of birth	
	Unknown, <= 2 months	
	Unknown, 2 - 12 months	
	Number of infants with a positive virological test result within 2 months of birth	19
	Number of infants with a negative virological test result within 2 months of birth	1,958
	Number of infants with a positive virological test result between 2 and 12 months of birth	40
	Number of infants with a negative virological test result between 2	437



	and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	139,049
	Age/Sex: 15-19 Male	306
	Age/Sex: 15-19 Female	703
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	3,690
	Aggregated Age/Sex: 15+ Male	37,045
	Aggregated Age/Sex: <15 Female	5,100
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	73,151
	Sum of Aggregated Age/Sex <15	8,790
	Sum of Aggregated Age/Sex 15+	110,196
	Sum of Aggregated Age/Sex disaggregates	118,986
	Age/Sex: <1	6
	Age/Sex: <1-9	7
	Age/Sex: 10-14 Male	993
	Age/Sex: 10-14 Female	971
	Aggregated Age/Sex: 1-14 Male	
	Age/Sex: 20-24 Male	480
	Age/Sex: 25-49 Male	4,414
	Age/Sex: 50+ Male	9
	Age/Sex: 20-24 Female	1,082
Age/Sex: 25-49 Female	11,080	
Age/Sex: 50+ Female	12	



TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	53,360
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	1,545
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	16,877
	Aggregated Age/Sex: <15 Female	2,388
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	32,542
	Sum of Aggregated Age/Sex <15	3,933
	Sum of Aggregated Age/Sex 15+	49,419
	Sum of Aggregated Age/Sex disaggregates	53,352
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	



	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	22,048
	By Age/Sex: <1	5
	By Age/Sex: 1-9	1
	By Age/Sex: 10-14 Male	52
	By Age/Sex: 15-19 Male	86
	By Age/Sex: 20-24 Male	372
	By Age/Sex: 25-49 Male	65
	By Age/Sex: 50+ Male	1
	By Age/Sex: 10-14 Female	67
	By Age/Sex: 15-19 Female	115
	By Age/Sex: 20-24 Female	782
	By Age/Sex: 25-49 Female	64
	By Age/Sex: 50+ Female	8
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	363
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	6,556
Aggregated Grouping by Age/Sex: <1 Female		
Aggregated Grouping by Age/Sex:	555	



	<15 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	12,940
	Pregnancy status	3
	Breastfeeding status	1
	FSW	880
	MSM	297
	People in prisons and other enclosed settings	
	TG	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	By Key populations: People who inject drugs (PWID)	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,023
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
By Age/Sex: 20-24 Female		



	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	142
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	3,273
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	197
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	5,401
	Sum of Aggregated Age/Sex disaggregates	9,013
	Pregnancy status	
	Breastfeeding status	
	FSW	
	MSM	
	People in prisons and other enclosed settings	
	TG	
	By Key populations: People who inject drugs (PWID)	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record	85 %



	and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	86,963
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	102,306
	Numerator: Indication: Routine	44,235
	Numerator: Indication: Targeted	1,696
	Numerator: Preg/BF by Indication: Pregnant Routine	0
	Numerator: Preg/BF by Indication: Breastfeeding Routine	0
	Numerator: Preg/BF by Indication: Pregnant Targeted	0
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	0
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	



	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	





	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	41
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	468
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	95
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,092
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,146
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	11,921
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	2,193
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	28,975
	Denominator: Indication: Routine	52,042
	Denominator: Indication: Targeted	1,995
	Denominator: Preg/BF by Indication: Pregnant Routine	0
	Denominator: Preg/BF by Indication: Breastfeeding Routine	0
	Denominator: Preg/BF by Indication: Pregnant Targeted	0
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	0
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	



	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	



	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	75
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	526
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	110
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,284
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,352
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	14,026
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,578
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	34,086
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	



Denominator Aggregated Age/Sex: <15 Male	
Denominator Aggregated Age/Sex: 15+ Male	
Denominator Aggregated Age/Sex: <15 Female	
Denominator Aggregated Age/Sex: 15+ Female	
<15, Routine, Unknown Sex	0
<15, Targeted, Unknown Sex	0
<15, Undocumented Test Indication, Female	1,911
<15, Undocumented Test Indication, Male	1,727
<15, Undocumented Test Indication, Unknown Sex	0
15+, Routine, Unknown Sex	0
15+, Targeted, Unknown Sex	0
15+, Undocumented Test Indication, Female	29,319
15+, Undocumented Test Indication, Male	15,312
15+, Undocumented Test Indication, Unknown Sex	0
Unknown Age, Routine, Female	0
Unknown Age, Routine, Male	0
Unknown Age, Routine, Unknown Sex	0
Unknown Age, Targeted, Female	0
Unknown Age, Targeted, Male	0
Unknown Age, Targeted, Unknown Sex	0
Unknown Age, Undocumented Test Indication, Female	0



Unknown Age, Undocumented Test Indication, Male	0
Unknown Age, Undocumented Test Indication, Unknown Sex	0
Breastfeeding, Undocumented Test Indication	0
Pregnant, Undocumented Test Indication	0
Undocumented Test Indication	48,269
<15, Routine, Unknown Sex	0
<15, Targeted, Unknown Sex	0
<15, Undocumented Test Indication, Female	1,626
<15, Undocumented Test Indication, Male	1,470
<15, Undocumented Test Indication, Unknown Sex	0
15+, Routine, Unknown Sex	0
15+, Targeted, Unknown Sex	0
15+, Undocumented Test Indication, Female	24,919
15+, Undocumented Test Indication, Male	13,016
15+, Undocumented Test Indication, Unknown Sex	0
Unknown Age, Routine, Female	0
Unknown Age, Routine, Male	0
Unknown Age, Routine, Unknown Sex	0
Unknown Age, Targeted, Female	0
Unknown Age, Targeted, Male	0
Unknown Age, Targeted, Unknown Sex	0



	Unknown Age, Undocumented Test Indication, Female	0
	Unknown Age, Undocumented Test Indication, Male	0
	Unknown Age, Undocumented Test Indication, Unknown Sex	0
	Breastfeeding, Undocumented Test Indication	0
	Pregnant, Undocumented Test Indication	0
	Undocumented Test Indication	41,032
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	85 %
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	38,352
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	45,120
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	



	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	



	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	1,717
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,507
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	24,672
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	10,459
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	38,352
	Numerator: Indication: Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	2
	Numerator: Preg/BF by Indication: Pregnant Targeted	





	Denominator: Indication: Routine	45,095
	Denominator: Indication: Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	



	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,017
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,774
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	29,028
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	12,301
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	



	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	
	<15, Routine, Unknown Sex	
	<15, Targeted, Unknown Sex	
	<15, Undocumented Test Indication, Female	
	<15, Undocumented Test Indication, Male	
	<15, Undocumented Test Indication, Unknown Sex	
	15+, Routine, Unknown Sex	
	15+, Targeted, Unknown Sex	
	15+, Undocumented Test Indication, Female	



	15+, Undocumented Test Indication, Male	
	15+, Undocumented Test Indication, Unknown Sex	
	Unknown Age, Routine, Female	
	Unknown Age, Routine, Male	
	Unknown Age, Routine, Unknown Sex	
	Unknown Age, Targeted, Female	
	Unknown Age, Targeted, Male	
	Unknown Age, Targeted, Unknown Sex	
	Unknown Age, Undocumented Test Indication, Female	
	Unknown Age, Undocumented Test Indication, Male	
	Unknown Age, Undocumented Test Indication, Unknown Sex	
	Breastfeeding, Undocumented Test Indication	
	Pregnant, Undocumented Test Indication	
	Undocumented Test Indication	
	<15, Routine, Unknown Sex	
	<15, Targeted, Unknown Sex	
	<15, Undocumented Test Indication, Female	
	<15, Undocumented Test Indication, Male	
	<15, Undocumented Test Indication, Unknown Sex	
	15+, Routine, Unknown Sex	
	15+, Targeted, Unknown Sex	



	15+, Undocumented Test Indication, Female	
	15+, Undocumented Test Indication, Male	
	15+, Undocumented Test Indication, Unknown Sex	
	Unknown Age, Routine, Female	
	Unknown Age, Routine, Male	
	Unknown Age, Routine, Unknown Sex	
	Unknown Age, Targeted, Female	0
	Unknown Age, Targeted, Male	
	Unknown Age, Targeted, Unknown Sex	
	Unknown Age, Undocumented Test Indication, Female	
	Unknown Age, Undocumented Test Indication, Male	
	Unknown Age, Undocumented Test Indication, Unknown Sex	
	Breastfeeding, Undocumented Test Indication	
	Pregnant, Undocumented Test Indication	
	Undocumented Test Indication	
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	80 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	13,748
	Total number of adults and children who initiated ART in the 12 months	17,273



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and	



	children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	



	<p>Age/Sex: 10-14 Male          (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 15-19 Male          (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 20-24 Male          (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 25-49 Male          (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the</p>	





	reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	



	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	9
	Numerator by Status: Breastfeeding	0
	Denominator by Status: Pregnant	0



	Denominator by Status: Breastfeeding	0
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	328
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,004
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	621
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,797
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	344
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	5,085



	those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,063
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,780
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	79 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,075
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,905
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female	



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male	



	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator:	





	Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	100
	Aggregated Age/Sex: 15+ Male	891



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	90
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,993
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	132
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,140
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	115



	those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,518



## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
6459	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	100,000
9872	Potentia Namibia Recruitment Consultancy	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
9876	Namibia Institute of Pathology	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
9940	Development Aid from People to People, Namibia	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10181	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	0
10389	Management Sciences for	NGO	U.S. Agency for International	GHP-State	0



	Health		Development		
10397	KNCV Tuberculosis Foundation	NGO	U.S. Agency for International Development	GHP-State	1,662,000
10780	University of Washington	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12752	Ministry of Health and Social Services, Namibia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13207	Polytechnic of Namibia	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13227	ITECH	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	0
13601	Society for Family Health	NGO	U.S. Agency for International Development	GHP-State	1,744,197
13752	Project HOPE	NGO	U.S. Agency for International Development	GHP-State	2,795,700



			International Development		
14390	University of Namibia	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14391	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
16756	Ministry of Health and Social Services, Namibia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,461,725
16771	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	860,000
16829	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	300,000
17529	JHPIEGO	University	U.S. Agency for International Development	GHP-State	1,866,200



17531	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	6,035,535
17532	University of North Carolina	University	U.S. Agency for International Development	GHP-State	1,800,000
18035	University of Washington	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	7,293,400
18036	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
18037	University of Washington	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	0
18039	United Nations Children's Fund	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
18040	World Health Organization	Multi-lateral Agency	U.S. Department of Health and	GHP-State	100,000



			Human Services/Centers for Disease Control and Prevention		
18088	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	0
18126	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	1,233,682
18354	Potentia Namibia Recruitment Consultancy	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	7,705,692
18355	Development Aid from People to People, Namibia	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,128,000
18356	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	607,000
18357	Namibia Institute of Pathology	Parastatal	U.S. Department of Health and Human Services/Centers	GHP-State	879,800





			for Disease Control and Prevention		
18358	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	250,000
18359	UNAIDS - Joint United Nations Programme on HIV/AIDS	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
18360	Health Research Inc./New York State Department of Health	Other USG Agency	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	300,000
18362	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
18400	TBD	TBD	Redacted	Redacted	Redacted
18401	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	1,460,800
18402	TBD	TBD	Redacted	Redacted	Redacted



18404	Population Council	NGO	U.S. Agency for International Development	GHP-State	575,000
18420	TBD	TBD	Redacted	Redacted	Redacted
18430	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
18608	Baylor University, College of Medicine	University	U.S. Agency for International Development	GHP-State	400,000
18611	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	223,089
18612	ICF Macro	Private Contractor	U.S. Agency for International Development	GHP-State	150,000
18658	TBD	TBD	Redacted	Redacted	Redacted



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 6459</b>	<b>Mechanism Name: Department of State/African Affairs</b>
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 100,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	100,000

### Cross-Cutting Budget Attribution(s)

Key Populations: FSW	20,000
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Training of health workers and community outreach workers
Key Populations: MSM and TG	20,000
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Gender: GBV	20,000
Focus Area:	Post GBV Care

Approved



Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Sub Area:	Implementation

### Budget Code Information

<b>Mechanism ID:</b> 6459			
<b>Mechanism Name:</b> Department of State/African Affairs			
<b>Prime Partner Name:</b> U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 9872	<b>Mechanism Name:</b> Cooperative Agreement 1U2GPS002722
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Potentia Namibia Recruitment Consultancy	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	9872		
<b>Mechanism Name:</b>	Cooperative Agreement 1U2GPS002722		
<b>Prime Partner Name:</b>	Potentia Namibia Recruitment Consultancy		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 9876</b>	<b>Mechanism Name: Cooperative Agreement 1U2GPS002058</b>
---------------------------	---

Approved



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Namibia Institute of Pathology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	9876		
<b>Mechanism Name:</b>	Cooperative Agreement 1U2GPS002058		
<b>Prime Partner Name:</b>	Namibia Institute of Pathology		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 9940</b>	<b>Mechanism Name: Cooperative Agreement</b>
---------------------------	--



	<b>1U2GPS0018665166</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Development Aid from People to People, Namibia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	9940		
<b>Mechanism Name:</b>	Cooperative Agreement 1U2GPS0018665166		
<b>Prime Partner Name:</b>	Development Aid from People to People, Namibia		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 10181</b>	<b>Mechanism Name: PEACE CORPS NAMIBIA</b>
Funding Agency: PC	Procurement Type: Cooperative Agreement
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 111,781</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 111,781</b>	
Funding Source	Funding Amount
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)





### Budget Code Information

<b>Mechanism ID:</b> 10181			
<b>Mechanism Name:</b> PEACE CORPS NAMIBIA			
<b>Prime Partner Name:</b> U.S. Peace Corps			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,500
PP_PREV_DSD	Age/sex: 15-19 Male	100
PP_PREV_DSD	Age/sex: 20-24 Male	760
PP_PREV_DSD	Age/sex: 25-49 Male	190
PP_PREV_DSD	Age/sex: 15-19 Female	320
PP_PREV_DSD	Age/sex: 20-24 Female	1,720
PP_PREV_DSD	Age/sex: 25-49 Female	410
PP_PREV_DSD	Sum of Age/Sex disaggregates	3,500
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,800
OVC_SERV_DSD	Age/Sex: 10-14 Male	200



OVC_SERV_DSD	Age/Sex: 15-17 Male	350
OVC_SERV_DSD	By: Age/sex: Male 18-24	150
OVC_SERV_DSD	Age/Sex: 10-14 Female	700
OVC_SERV_DSD	Age/Sex: 15-17 Female	850
OVC_SERV_DSD	By: Age/sex: 18-24 Female	550
OVC_SERV_DSD	Sum of Age/Sex disaggregates	2,100
OVC_SERV_DSD	Program Completion: Active	2,800

**Implementing Mechanism Details**

<b>Mechanism ID: 10389</b>	<b>Mechanism Name: Systems to Improve Access to Pharmaceuticals and Services</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 10389</b>
----------------------------



<b>Mechanism Name:</b> Systems to Improve Access to Pharmaceuticals and Services			
<b>Prime Partner Name:</b> Management Sciences for Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 10397</b>	<b>Mechanism Name: Challenge TB Fund</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: KNCV Tuberculosis Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,662,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,662,000</b>	
Funding Source	Funding Amount
GHP-State	1,662,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID: 10397</b>			
<b>Mechanism Name: Challenge TB Fund</b>			
<b>Prime Partner Name: KNCV Tuberculosis Foundation</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	1,512,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	150,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 10780</b>	<b>Mechanism Name: Cooperative Agreement 1U58PS001452</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 10780			
<b>Mechanism Name:</b> Cooperative Agreement 1U58PS001452			
<b>Prime Partner Name:</b> University of Washington			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 12752	<b>Mechanism Name:</b> Cooperative Agreement 1U2GPS003014
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health and Social Services, Namibia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 0	<b>Total Mechanism Pipeline:</b> N/A
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount
GHP-State	0



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 12752			
<b>Mechanism Name:</b> Cooperative Agreement 1U2GPS003014			
<b>Prime Partner Name:</b> Ministry of Health and Social Services, Namibia			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 13207	<b>Mechanism Name:</b> Cooperative Agreement 1U2GPS002902
----------------------------	---

Approved



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Polytechnic of Namibia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13207		
<b>Mechanism Name:</b>	Cooperative Agreement 1U2GPS002902		
<b>Prime Partner Name:</b>	Polytechnic of Namibia		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details



<b>Mechanism ID: 13227</b>	<b>Mechanism Name: I-TECH: Support to MOHSS National Health Training Center (NHTC)</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: ITECH	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13227		
<b>Mechanism Name:</b>	I-TECH: Support to MOHSS National Health Training Center (NHTC)		
<b>Prime Partner Name:</b>	ITECH		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>





Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13601</b>	<b>Mechanism Name: Strengthening HIV Prevention for Key Populations</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Society for Family Health	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,744,197</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,744,197</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,744,197

### Cross-Cutting Budget Attribution(s)

Key Populations: FSW	750,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	450,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Monitoring and evaluation of MSM/TG programs

### Budget Code Information

<b>Mechanism ID:</b>	<b>13601</b>
<b>Mechanism Name:</b>	<b>Strengthening HIV Prevention for Key Populations</b>
<b>Prime Partner Name:</b>	<b>Society for Family Health</b>



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	236,100	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	384,937	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	397,594	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	725,566	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	500
PrEP_NEW_DSD	Male 20-24	32
PrEP_NEW_DSD	Male 25-49	83
PrEP_NEW_DSD	Female 20-24	150
PrEP_NEW_DSD	Female 25-49	235
PrEP_NEW_DSD	FSW	325
PrEP_NEW_DSD	MSM	115
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	13,208
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group	3,729



	level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	9,479
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	16,767
HTC_TST_DSD	By Test Result: Positive	1,746
HTC_TST_DSD	Sum of Test Result disaggregates	1,746
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	3,031
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	241
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	1,631
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	125
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	5,069
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	397
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	2,722
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	204
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	1,727
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive	496
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	932



HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	280
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,217
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	294
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	923
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,217
TX_NEW_DSD	FSW	880
TX_NEW_DSD	MSM	297

### Implementing Mechanism Details

<b>Mechanism ID: 13752</b>	<b>Mechanism Name: Adherence &amp; Retention Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Project HOPE	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,795,700</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,795,700</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,795,700

### Cross-Cutting Budget Attribution(s)

Gender: GBV	1
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	1
Focus Area:	Equity in HIV prevention, care, treatment and



	support
Sub Area:	Capacity building
Economic Strengthening	1

### Budget Code Information

<b>Mechanism ID:</b> 13752			
<b>Mechanism Name:</b> Adherence & Retention Project			
<b>Prime Partner Name:</b> Project HOPE			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	2,045,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	155,700	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	595,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	15,869
HTC_TST_DSD	By Test Result: Positive	756
HTC_TST_DSD	Sum of Test Result disaggregates	756
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: <15, Female, Negative	2,371
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: <15, Female, Positive	92



HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: <15, Male, Negative	1,608
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: <15, Male, Positive	92
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	6,255
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	237
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	4,589
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	211
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	22,169
OVC_SERV_DSD	Age/Sex: 10-14 Male	2,216
OVC_SERV_DSD	Age/Sex: 15-17 Male	2,217
OVC_SERV_DSD	By: Age/sex: Male 18-24	1,107
OVC_SERV_DSD	By: Age/sex: Male 25+	222
OVC_SERV_DSD	Age/Sex: 10-14 Female	2,217
OVC_SERV_DSD	Age/Sex: 15-17 Female	6,652
OVC_SERV_DSD	By: Age/sex: 18-24 Female	1,664
OVC_SERV_DSD	By: Age/sex: 25+ Female	1,441
OVC_SERV_DSD	Sum of Age/Sex disaggregates	13,302
OVC_SERV_DSD	Age/Sex: <1	443
OVC_SERV_DSD	Age/Sex: 1-9	3,990
OVC_SERV_DSD	Program Completion: Active	15,520
OVC_SERV_DSD	Program Completion: Graduation	3,990
OVC_SERV_DSD	Program Completion: Transferred	2,217
OVC_SERV_DSD	Program Completion: Exited without graduation	442

### Implementing Mechanism Details

<b>Mechanism ID: 14390</b>	<b>Mechanism Name: Cooperative Agreement</b>
----------------------------	--



	<b>U2GGH001182</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Namibia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	14390		
<b>Mechanism Name:</b>	Cooperative Agreement U2GGH001182		
<b>Prime Partner Name:</b>	University of Namibia		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**



Approved



<b>Mechanism ID: 14391</b>	<b>Mechanism Name: University of California-San Francisco</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	14391		
<b>Mechanism Name:</b>	University of California-San Francisco		
<b>Prime Partner Name:</b>	University of California at San Francisco		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0

### Implementing Mechanism Indicator Information

(No data provided.)



**Implementing Mechanism Details**

<b>Mechanism ID: 16756</b>	<b>Mechanism Name: Improving the Quality of Namibia's Essential Health Services and Systems (IQ-NEHSS)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health and Social Services, Namibia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 4,461,725</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,461,725</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,461,725

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	16756		
<b>Mechanism Name:</b>	Improving the Quality of Namibia's Essential Health Services and Systems (IQ-NEHSS)		
<b>Prime Partner Name:</b>	Ministry of Health and Social Services, Namibia		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	72,696	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HVTB	262,600	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	46,184	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	420,023	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	55,056	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	200,003	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	631,004	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	314,248	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	435,200	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,645,605	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	379,106	0

### Implementing Mechanism Indicator Information



Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,396
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,152
PMTCT_ART_DSD	New on ART	522
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	874
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,658
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,755
PMTCT_ART_TA	New on ART	658
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	2,000
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,152
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	0
PMTCT_STAT_DSD	By Age (Denominator): <15-19	1,213
PMTCT_STAT_DSD	By Age (Denominator): 20-24	2,056
PMTCT_STAT_DSD	By Age (Denominator): 25-49	3,099
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	32
PMTCT_STAT_DSD	By Number of known positives: 20-24	129
PMTCT_STAT_DSD	By Number of known positives: 25-49	815
PMTCT_STAT_DSD	By Number of known positives: 50+	0



PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	76
PMTCT_STAT_DSD	By Number of new positives: 20-24	144
PMTCT_STAT_DSD	By Number of new positives: 25-49	235
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	0
PMTCT_STAT_DSD	By Number of new negative: 15-19	890
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,512
PMTCT_STAT_DSD	By Number of new negative: 25-49	2,325
PMTCT_STAT_DSD	By Number of new negative: 50+	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	0
PMTCT_STAT_DSD	By Age (Numerator): 15-19	970
PMTCT_STAT_DSD	By Age (Numerator): 20-24	1,742
PMTCT_STAT_DSD	By Age (Numerator): 25-49	3,329
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,755
PMTCT_STAT_TA	By Age (Denominator): <10	0
PMTCT_STAT_TA	By Age (Denominator): 10-14	0
PMTCT_STAT_TA	By Age (Denominator): 15-19	2,933
PMTCT_STAT_TA	By Age (Denominator): 20-24	5,370
PMTCT_STAT_TA	By Age (Denominator): 25-49	9,016
PMTCT_STAT_TA	By Age (Denominator): 50+	0
PMTCT_STAT_TA	By known positives: <10	0
PMTCT_STAT_TA	By known positives: 10-14	0
PMTCT_STAT_TA	By known positives: 15-19	52
PMTCT_STAT_TA	By known positives: 20-24	168
PMTCT_STAT_TA	By known positives: 25-49	1,716



PMTCT_STAT_TA	By known positives: 50+	0
PMTCT_STAT_TA	By new positives: <10	0
PMTCT_STAT_TA	By new positives: 10-14	0
PMTCT_STAT_TA	By new positives: 15-19	111
PMTCT_STAT_TA	By new positives: 20-24	218
PMTCT_STAT_TA	By new positives: 25-49	476
PMTCT_STAT_TA	By new positives: 50+	0
PMTCT_STAT_TA	By new negatives: <10	0
PMTCT_STAT_TA	By new negatives: 10-14	0
PMTCT_STAT_TA	By new negatives: 15-19	2,365
PMTCT_STAT_TA	By new negatives: 20-24	4,245
PMTCT_STAT_TA	By new negatives: 25-49	6,972
PMTCT_STAT_TA	By new negatives: 50+	0
PMTCT_STAT_TA	By Age (Numerator): <10	0
PMTCT_STAT_TA	By Age (Numerator): 10-14	0
PMTCT_STAT_TA	By Age (Numerator): : 15-19	2,617
PMTCT_STAT_TA	By Age (Numerator): 20-24	4,726
PMTCT_STAT_TA	By Age (Numerator): 25-49	9,206
PMTCT_STAT_TA	By Age (Numerator): 50+	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	33,134
HTC_TST_DSD	By Test Result: Positive	2,369
HTC_TST_DSD	Sum of Test Result disaggregates	2,369
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	1,353
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	48
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	819
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	36
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other	13,413



	PITC: 15+, Female, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	904
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	7,827
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	640
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	15
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	8
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <15, Negative	224
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: <15, Positive	7
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	1,038
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	32
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	321
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	1



HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	223
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	1
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	1,161
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	99
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	744
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	60
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	4,389
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	453
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	103,766
HTC_TST_TA	By Test Result: Positive	7,691
HTC_TST_TA	Sum of Test Result disaggregates	7,691
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Negative	64
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Positive	13
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Negative	61
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Positive	6
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Negative	759
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Positive	121
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Positive	393





	Male, Negative	
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Positive	56
HTC_TST_TA	Service Delivery Point (Facility) Malnutrition: Negative	5
HTC_TST_TA	Service Delivery Point (Facility) Malnutrition: Positive	1
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Negative	4,030
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Positive	147
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Negative	2,387
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Positive	119
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	37,526
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive	3,056
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	25,576
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive	1,769
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	159
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	3
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Female, Negative	7
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Female, Positive	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Male, Negative	8
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Male, Positive	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Negative	106
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Positive	19



	Female, Positive	
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Negative	115
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Positive	20
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VMMC: <15, Negative	182
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VMMC: <15, Positive	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VMMC: 15+, Negative	2,771
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VMMC: 15+, Positive	209
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	3,712
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	388
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	2,170
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	260
HTC_TST_TA	Service Delivery Point Agg Age (Facility) ANC: 15+, Negative	12,139
HTC_TST_TA	Service Delivery Point Agg Age (Facility) ANC: 15+, Positive	852
TB_STAT_DSD	Number of registered new and relapsed TB cases with	510



	documented HIV status, during the reporting period.	
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,117
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,343
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	2,437
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	48
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	21
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	189
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	169
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	18
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	165
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	46
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	183
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	274
TB_ART_DSD	The number of registered new and relapse TB cases	297



	with documented HIV-positive status during TB treatment during the reporting period	
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,037
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,143
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,397
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	18
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	1,151
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	19
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	209
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,454
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	19
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	1,958
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	40
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	437
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	15,636
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	358
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	4,668
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	542
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	10,068



TX_CURR_DSD	Sum of Aggregated Age/Sex <15	900
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	14,736
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	15,636
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	53,360
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,545
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	16,877
TX_CURR_TA	Aggregated Age/Sex: <15 Female	2,388
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	32,542
TX_CURR_TA	Sum of Aggregated Age/Sex <15	3,933
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	49,419
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	53,352
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,497
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	36
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,215
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	50
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,179
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,480
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,023
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	142
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	3,273
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	197
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	5,401
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	9,013
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	12,023
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	14,144



TX_PVLS_DSD	Numerator: Indication: Routine	12,023
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	374
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,030
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	389
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	8,230
TX_PVLS_DSD	Denominator: Indication: Routine	14,144
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	442
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,566
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	456
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	9,680
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	38,352
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	45,120
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	1,717
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,507
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	24,672
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	10,459
TX_PVLS_TA	Numerator: Indication: Routine	38,352



TX_PVLS_TA	Numerator: Preg/BF by Indication: Pregnant Routine	2
TX_PVLS_TA	Denominator: Indication: Routine	45,095
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,017
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,774
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	29,028
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	12,301
TX_PVLS_TA	Unknown Age, Targeted, Female	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,239
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,628
TX_RET_DSD	Numerator by Status: Pregnant	9
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	321
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	893
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	7



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	418
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	23
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,179
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,075
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,905
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	100
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	891
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	90
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,993
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total	132





	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,140
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	115
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,518

**Implementing Mechanism Details**

<b>Mechanism ID: 16771</b>	<b>Mechanism Name: Namibia Mechanism for Public Health Assistance, Capacity, and Technical Support (NAM-PHACTS)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 860,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 860,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

Approved



GHP-State	860,000
-----------	---------

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	16771		
<b>Mechanism Name:</b>	Namibia Mechanism for Public Health Assistance, Capacity, and		
<b>Prime Partner Name:</b>	Technical Support (NAM-PHACTS)		
	University of California at San Francisco		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	400,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	460,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16829</b>	<b>Mechanism Name: Health Financing and Governance</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Approved



<b>Total All Funding Sources: 300,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	300,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 16829			
<b>Mechanism Name:</b> Health Financing and Governance			
<b>Prime Partner Name:</b> Abt Associates			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	300,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17529	<b>Mechanism Name:</b> Maternal and Child Survival Program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 1,866,200</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,866,200</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,866,200

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	1
Water	50,000

**Budget Code Information**

<b>Mechanism ID: 17529</b>			
<b>Mechanism Name: Maternal and Child Survival Program</b>			
<b>Prime Partner Name: JHPIEGO</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	250,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	271,200	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,045,000	0



## Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	100
PrEP_NEW_DSD	Male 15-19	3
PrEP_NEW_DSD	Male 20-24	12
PrEP_NEW_DSD	Male 25-49	21
PrEP_NEW_DSD	Male 50+	4
PrEP_NEW_DSD	Female 15-19	5
PrEP_NEW_DSD	Female 20-24	18
PrEP_NEW_DSD	Female 25-49	31
PrEP_NEW_DSD	Female 50+	6
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	45,234
PP_PREV_DSD	Age/sex: 10-14 Male	1,099
PP_PREV_DSD	Age/sex: 15-19 Male	4,390
PP_PREV_DSD	Age/sex: 20-24 Male	6,583
PP_PREV_DSD	Age/sex: 25-49 Male	6,579
PP_PREV_DSD	Age/sex: 10-14 Female	2,194
PP_PREV_DSD	Age/sex: 15-19 Female	7,679
PP_PREV_DSD	Age/sex: 20-24 Female	8,778
PP_PREV_DSD	Age/sex: 25-49 Female	6,583
PP_PREV_DSD	Sum of Age/Sex disaggregates	43,885
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,545
HTC_TST_DSD	By Test Result: Positive	77
HTC_TST_DSD	Sum of Test Result disaggregates	77



HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	229
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	13
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	152
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	8
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	652
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	35
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	435
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	21
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	500
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	52
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	148
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	77
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	223
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	500
TX_NEW_DSD	Pregnancy status	3
TX_NEW_DSD	Breastfeeding status	1

### Implementing Mechanism Details

<b>Mechanism ID: 17531</b>	<b>Mechanism Name: USAID HIV Clinical Services Technical Assistance Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
<b>Total All Funding Sources: 6,035,535</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 6,035,535</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	6,035,535

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	1
----------------------------	---

**Budget Code Information**

<b>Mechanism ID: 17531</b>			
<b>Mechanism Name: USAID HIV Clinical Services Technical Assistance Project</b>			
<b>Prime Partner Name: IntraHealth International, Inc</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	350,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	252,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	480,619	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	432,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	228,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,762,916	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	330,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,991
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	11,772
PMTCT_ART_DSD	New on ART	350
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,641
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	11,772
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	0
PMTCT_STAT_DSD	By Age (Denominator): <15-19	2,457
PMTCT_STAT_DSD	By Age (Denominator): 20-24	3,709
PMTCT_STAT_DSD	By Age (Denominator): 25-49	6,191
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0





PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	348
PMTCT_STAT_DSD	By Number of known positives: 20-24	541
PMTCT_STAT_DSD	By Number of known positives: 25-49	907
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	60
PMTCT_STAT_DSD	By Number of new positives: 20-24	107
PMTCT_STAT_DSD	By Number of new positives: 25-49	188
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	0
PMTCT_STAT_DSD	By Number of new negative: 15-19	1,918
PMTCT_STAT_DSD	By Number of new negative: 20-24	2,885
PMTCT_STAT_DSD	By Number of new negative: 25-49	4,818
PMTCT_STAT_DSD	By Number of new negative: 50+	0
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	0
PMTCT_STAT_DSD	By Age (Numerator): 15-19	2,326
PMTCT_STAT_DSD	By Age (Numerator): 20-24	3,533
PMTCT_STAT_DSD	By Age (Numerator): 25-49	5,913
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	950
PrEP_NEW_DSD	Male 15-19	54
PrEP_NEW_DSD	Male 20-24	111



PrEP_NEW_DSD	Male 25-49	135
PrEP_NEW_DSD	Male 50+	77
PrEP_NEW_DSD	Female 15-19	72
PrEP_NEW_DSD	Female 20-24	153
PrEP_NEW_DSD	Female 25-49	179
PrEP_NEW_DSD	Female 50+	169
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	79,147
HTC_TST_DSD	By Test Result: Positive	7,875
HTC_TST_DSD	Sum of Test Result disaggregates	7,875
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	387
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	50
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	732
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	92
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	9,179
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	639
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	3,967
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	422
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient:	0



	Unknown Age, Male, Positive	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	820
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	78
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	1,539
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	174
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	20,084
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	2,613
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	8,035
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	1,021
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	498
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0



HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	10
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	29
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	501
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	71
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	161
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	16
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Positive	0



HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	70
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	97
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	27
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female,	167



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	92
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	170
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	17
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	283
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15,	21



	Male, Positive	
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	4,839
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	528
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	1,602
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	198
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	3
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	4
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	7,472
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	787
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	548
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15,	49





	Female, Positive	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	792
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	87
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	12,729
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	1,341
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	4,931
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	534
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Positive	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,702
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,817
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	88
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	924
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	75



TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	615
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	110
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	985
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	89
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	633
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	638
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	698
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	146
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	263
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	63
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with	166



	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	167
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	291
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	70
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	170
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,032
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	5
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	1,448
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	7
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	572
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	47,332
TX_CURR_DSD	Age/Sex: 15-19 Male	20
TX_CURR_DSD	Age/Sex: 15-19 Female	35



TX_CURR_DSD	Sum of age/sex disaggregates	55
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,659
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	14,010
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,603
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	28,562
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	4,262
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	42,572
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	46,834
TX_CURR_DSD	Age/Sex: <1	6
TX_CURR_DSD	Age/Sex: <1-9	7
TX_CURR_DSD	Age/Sex: 10-14 Male	8
TX_CURR_DSD	Age/Sex: 10-14 Female	12
TX_CURR_DSD	Age/Sex: 20-24 Male	80
TX_CURR_DSD	Age/Sex: 25-49 Male	61
TX_CURR_DSD	Age/Sex: 50+ Male	9
TX_CURR_DSD	Age/Sex: 20-24 Female	146
TX_CURR_DSD	Age/Sex: 25-49 Female	102
TX_CURR_DSD	Age/Sex: 50+ Female	12
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	8,541
TX_NEW_DSD	By Age/Sex: <1	5
TX_NEW_DSD	By Age/Sex: 1-9	1
TX_NEW_DSD	By Age/Sex: 10-14 Male	1
TX_NEW_DSD	By Age/Sex: 15-19 Male	2
TX_NEW_DSD	By Age/Sex: 20-24 Male	31
TX_NEW_DSD	By Age/Sex: 25-49 Male	65
TX_NEW_DSD	By Age/Sex: 50+ Male	1
TX_NEW_DSD	By Age/Sex: 10-14 Female	1
TX_NEW_DSD	By Age/Sex: 15-19 Female	4
TX_NEW_DSD	By Age/Sex: 20-24 Female	46
TX_NEW_DSD	By Age/Sex: 25-49 Female	64
TX_NEW_DSD	By Age/Sex: 50+ Female	8



TX_NEW_DSD	Sum of Age/Sex disaggregates	223
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	129
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,849
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	219
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	5,116
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	8,313
TX_NEW_DSD	Pregnancy status	0
TX_NEW_DSD	Breastfeeding status	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	33,908
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	39,893
TX_PVLS_DSD	Numerator: Indication: Routine	32,212
TX_PVLS_DSD	Numerator: Indication: Targeted	1,696
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	41
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	468
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	95
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,092
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	772



TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	8,891
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	1,804
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	20,745
TX_PVLS_DSD	Denominator: Indication: Routine	37,898
TX_PVLS_DSD	Denominator: Indication: Targeted	1,995
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	75
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	526
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	110
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,284
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	910
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	10,460
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,122
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	24,406
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0



TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0



TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,719
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,297
TX_RET_DSD	Numerator by Status: Pregnant	0
TX_RET_DSD	Numerator by Status: Breastfeeding	0
TX_RET_DSD	Denominator by Status: Pregnant	0
TX_RET_DSD	Denominator by Status: Breastfeeding	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	162
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,852
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	377
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,328
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the	126





	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,365
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,742
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,064

**Implementing Mechanism Details**

<b>Mechanism ID: 17532</b>	<b>Mechanism Name: Measure Evaluation Phase 4</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,800,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,800,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,800,000



### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17532		
<b>Mechanism Name:</b>	Measure Evaluation Phase 4		
<b>Prime Partner Name:</b>	University of North Carolina		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	600,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	500,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	700,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18035</b>	<b>Mechanism Name: Namibia Mechanism for Public Health Assistance, Capacity, and Technical Support (NAM-PHACTS)</b>		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: University of Washington			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			

Approved



G2G: No	Managing Agency:
<b>Total All Funding Sources: 7,293,400</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 7,293,400</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	7,293,400

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18035		
<b>Mechanism Name:</b>	Namibia Mechanism for Public Health Assistance, Capacity, and		
<b>Prime Partner Name:</b>	Technical Support (NAM-PHACTS)		
	University of Washington		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	125,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	80,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	250,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	690,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	CIRC	1,323,400	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	400,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	1,350,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	175,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	2,700,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	200,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,802
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	24,825
PMTCT_ART_DSD	New on ART	1,219
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,583
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	24,825
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	14,311



PMTCT_STAT_DSD	By Age (Denominator): <15-19	1,814
PMTCT_STAT_DSD	By Age (Denominator): 20-24	3,450
PMTCT_STAT_DSD	By Age (Denominator): 25-49	6,580
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	1,675
PMTCT_STAT_DSD	By Number of known positives: 15-19	95
PMTCT_STAT_DSD	By Number of known positives: 20-24	350
PMTCT_STAT_DSD	By Number of known positives: 25-49	727
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	644
PMTCT_STAT_DSD	By Number of new positives: 15-19	30
PMTCT_STAT_DSD	By Number of new positives: 20-24	167
PMTCT_STAT_DSD	By Number of new positives: 25-49	354
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	11,254
PMTCT_STAT_DSD	By Number of new negative: 15-19	1,567
PMTCT_STAT_DSD	By Number of new negative: 20-24	2,764
PMTCT_STAT_DSD	By Number of new negative: 25-49	5,198
PMTCT_STAT_DSD	By Age (Numerator): 15-19	1,692
PMTCT_STAT_DSD	By Age (Numerator): 20-24	3,281
PMTCT_STAT_DSD	By Age (Numerator): 25-49	6,279
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	11,412
VMMC_CIRC_DSD	By Age: 10-14	3,994
VMMC_CIRC_DSD	By Age: 15-19	3,994
VMMC_CIRC_DSD	By Age: 20-24	1,712
VMMC_CIRC_DSD	By Age: 25-29	1,142
VMMC_CIRC_DSD	By Age: 30-49	570
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	9,700
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	11,412
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	11,412
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	40,118



PP_PREV_DSD	Age/sex: 10-14 Male	1,956
PP_PREV_DSD	Age/sex: 15-19 Male	4,889
PP_PREV_DSD	Age/sex: 20-24 Male	978
PP_PREV_DSD	Age/sex: 25-49 Male	978
PP_PREV_DSD	Age/sex: 10-14 Female	1,956
PP_PREV_DSD	Age/sex: 15-19 Female	4,889
PP_PREV_DSD	Age/sex: 20-24 Female	2,935
PP_PREV_DSD	Age/sex: 25-49 Female	978
PP_PREV_DSD	Sum of Age/Sex disaggregates	19,559
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	95,062
HTC_TST_DSD	By Test Result: Positive	5,948
HTC_TST_DSD	Sum of Test Result disaggregates	5,948
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	42
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	47
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	576
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	193
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	753
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24,	118



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,247
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	150
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	63
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	7
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	68
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	9
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	1,521
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	218
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	1,648
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	238
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,645
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	83
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	887
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	634
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	341



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	3,961
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	214
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,134
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	121
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	2,737
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	144
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	1,480
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	72
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	23,042
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	1,162
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	12,410
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	622
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	4,968
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	123
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male,	0





	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	47
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	35
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	55
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	49
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	124
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+,	105



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	300
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	418
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	19
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	913
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	178
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	140
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	281
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	73
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	386
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	87



	Positive	
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	1,515
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	267
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	3,544
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	626
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,567
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	2,764
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	167
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	5,198
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	354
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	11,256
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	642
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,695
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,871
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	13



TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	481
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	23
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	303
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	17
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	490
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	27
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	317
GEND_GBV_DSD	Number of people receiving post-GBV care	400
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	140
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	260
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	200
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	6
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	4
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	20
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	80
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	20
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	50



GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	170
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	40
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	100
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	40
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,436
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,560
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,769
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	29
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	2,867
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	52
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	821
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	76,081
TX_CURR_DSD	Age/Sex: 15-19 Male	286
TX_CURR_DSD	Age/Sex: 15-19 Female	668
TX_CURR_DSD	Sum of age/sex disaggregates	954
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,673
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	18,367
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,955
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	34,521
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,628
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	52,888



TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	56,516
TX_CURR_DSD	Age/Sex: 10-14 Male	985
TX_CURR_DSD	Age/Sex: 10-14 Female	959
TX_CURR_DSD	Age/Sex: 20-24 Male	400
TX_CURR_DSD	Age/Sex: 25-49 Male	4,353
TX_CURR_DSD	Age/Sex: 20-24 Female	936
TX_CURR_DSD	Age/Sex: 25-49 Female	10,978
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	8,293
TX_NEW_DSD	By Age/Sex: 10-14 Male	51
TX_NEW_DSD	By Age/Sex: 15-19 Male	84
TX_NEW_DSD	By Age/Sex: 20-24 Male	341
TX_NEW_DSD	By Age/Sex: 10-14 Female	66
TX_NEW_DSD	By Age/Sex: 15-19 Female	111
TX_NEW_DSD	By Age/Sex: 20-24 Female	736
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,389
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	146
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,050
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	209
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	4,499
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,904
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	41,032
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	48,269
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	1,911
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	1,727
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	29,319
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	15,312
TX_PVLS_DSD	Undocumented Test Indication	48,269



TX_PVLS_DSD	<15, Undocumented Test Indication, Female	1,626
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	1,470
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	24,919
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	13,016
TX_PVLS_DSD	Undocumented Test Indication	41,032
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,790
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	7,348
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	160
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,831
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	223
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,576
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	211
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,302
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the	298



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,537

**Implementing Mechanism Details**

<b>Mechanism ID: 18036</b>	<b>Mechanism Name: Cooperative Agreement UGH000710</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 18036
----------------------------





<b>Mechanism Name:</b>	<b>Cooperative Agreement UGH000710</b>		
<b>Prime Partner Name:</b>	<b>African Society for Laboratory Medicine</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18037</b>	<b>Mechanism Name: HRSA/I-TECH</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information



<b>Mechanism ID: 18037</b>			
<b>Mechanism Name: HRSA/I-TECH</b>			
<b>Prime Partner Name: University of Washington</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18039</b>	<b>Mechanism Name: UNICEF</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations Children's Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 100,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 100,000</b>	
Funding Source	Funding Amount
GHP-State	100,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information



<b>Mechanism ID: 18039</b>			
<b>Mechanism Name: UNICEF</b>			
<b>Prime Partner Name: United Nations Children's Fund</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	100,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18040</b>	<b>Mechanism Name: WHO</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 100,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	100,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b>	18040		
<b>Mechanism Name:</b>	WHO		
<b>Prime Partner Name:</b>	World Health Organization		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	100,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18088</b>	<b>Mechanism Name: 4Children</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 18088			
<b>Mechanism Name:</b> 4Children			
<b>Prime Partner Name:</b> Catholic Relief Services			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 18126		<b>Mechanism Name:</b> AIDSFree	
Funding Agency: USAID		Procurement Type: Cooperative Agreement	
Prime Partner Name: John Snow Inc (JSI)			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	

<b>Total All Funding Sources:</b> 1,233,682		<b>Total Mechanism Pipeline:</b> N/A	
<b>Applied Pipeline Amount:</b> 0			
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 1,233,682			
Funding Source	Funding Amount		
GHP-State	1,233,682		

### Cross-Cutting Budget Attribution(s)

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b>	18126		
<b>Mechanism Name:</b>	AIDSFree		
<b>Prime Partner Name:</b>	John Snow Inc (JSI)		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	1,233,682	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	20,152
VMMC_CIRC_DSD	By Age: 10-14	2,015
VMMC_CIRC_DSD	By Age: 15-19	8,060
VMMC_CIRC_DSD	By Age: 20-24	6,046
VMMC_CIRC_DSD	By Age: 25-29	2,831
VMMC_CIRC_DSD	By Age: 30-49	1,200
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	16,121
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	20,152
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	20,152

### Implementing Mechanism Details

<b>Mechanism ID: 18354</b>	<b>Mechanism Name: Human Resources Support</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Potentia Namibia Recruitment Consultancy	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	

Approved



G2G: No	Managing Agency:
<b>Total All Funding Sources: 7,705,692</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 7,705,692</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	7,705,692

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18354</b>			
<b>Mechanism Name: Human Resources Support</b>			
<b>Prime Partner Name: Potentia Namibia Recruitment Consultancy</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	600,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	270,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	316,619	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	209,085	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVCT	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	140,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	5,612,861	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	457,127	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18355</b>	<b>Mechanism Name: Community Based Interventions</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Development Aid from People to People, Namibia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,128,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,128,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,128,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)





### Budget Code Information

<b>Mechanism ID:</b>	18355		
<b>Mechanism Name:</b>	Community Based Interventions		
<b>Prime Partner Name:</b>	Development Aid from People to People, Namibia		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	475,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	50,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	145,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	150,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	120,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	598,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	150,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	90,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	HTXS	350,000	0
-----------	------	---------	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	61,362
PP_PREV_DSD	Age/sex: 15-19 Male	1,412
PP_PREV_DSD	Age/sex: 20-24 Male	5,395
PP_PREV_DSD	Age/sex: 25-49 Male	8,274
PP_PREV_DSD	Age/sex: 15-19 Female	3,952
PP_PREV_DSD	Age/sex: 20-24 Female	18,046
PP_PREV_DSD	Age/sex: 25-49 Female	24,283
PP_PREV_DSD	Sum of Age/Sex disaggregates	61,362
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	47,535
HTC_TST_DSD	By Test Result: Positive	4,726
HTC_TST_DSD	Sum of Test Result disaggregates	4,726
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative	510
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive	28
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative	350
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive	17
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative	16,659
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive	1,611



HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Negative	12,936
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Positive	1,187
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	9,099
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive	1,120
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	5,956
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	785

### Implementing Mechanism Details

<b>Mechanism ID: 18356</b>	<b>Mechanism Name: Technical Assistance to provide High Quality VMMC</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 607,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 607,000</b>	



Funding Source	Funding Amount
GHP-State	607,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18356		
<b>Mechanism Name:</b>	Technical Assistance to provide High Quality VMMC		
<b>Prime Partner Name:</b>	JHPIEGO		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	607,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	12,039
VMMC_CIRC_DSD	By Age: 15-19	3,798
VMMC_CIRC_DSD	By Age: 20-24	4,818
VMMC_CIRC_DSD	By Age: 25-29	3,423
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	8,616
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	12,039
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	12,039

### Implementing Mechanism Details

<b>Mechanism ID:</b> 18357	<b>Mechanism Name:</b> Expansion of HIV/AIDS, STI &
----------------------------	---



<b>TB Laboratory Activities</b>	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Namibia Institute of Pathology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 879,800</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 879,800</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	879,800

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18357		
<b>Mechanism Name:</b>	Expansion of HIV/AIDS, STI & TB Laboratory Activities		
<b>Prime Partner Name:</b>	Namibia Institute of Pathology		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	549,800	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	HVSI	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18358</b>	<b>Mechanism Name: EGPAF</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 250,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 250,000</b>	
Funding Source	Funding Amount
GHP-State	250,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 18358</b>
----------------------------



<b>Mechanism Name:</b> EGPAF			
<b>Prime Partner Name:</b> Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	250,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 18359	<b>Mechanism Name:</b> UNAIDS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 100,000	<b>Total Mechanism Pipeline:</b> N/A
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 100,000	
Funding Source	Funding Amount
GHP-State	100,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 18359
----------------------------



<b>Mechanism Name:</b>	<b>UNAIDS</b>		
<b>Prime Partner Name:</b>	<b>UNAIDS - Joint United Nations Programme on HIV/AIDS</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	40,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	40,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	20,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18360</b>	<b>Mechanism Name: Quality Improvement and Capacity for Impact Project (QICIP)</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Research Inc./New York State Department of Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 300,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	300,000





**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 18360			
<b>Mechanism Name:</b> Quality Improvement and Capacity for Impact Project (QICIP)			
<b>Prime Partner Name:</b> Health Research Inc./New York State Department of Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	300,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 18362	<b>Mechanism Name:</b> Association of Public Health laboratories (APHL)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	0



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18362		
<b>Mechanism Name:</b>	Association of Public Health laboratories (APHL)		
<b>Prime Partner Name:</b>	Association of Public Health Laboratories		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 18400</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 18401</b>	<b>Mechanism Name: Global Health Supply Chain-Procurement Supply Management</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
<b>Total All Funding Sources: 1,460,800</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,460,800</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,460,800

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18401</b>			
<b>Mechanism Name: Global Health Supply Chain-Procurement Supply Management</b>			
<b>Prime Partner Name: Global Health Supply Chain Program</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	174,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	116,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	336,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	204,800	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	630,000	0



## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID: 18402</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

## Implementing Mechanism Details

<b>Mechanism ID: 18404</b>	<b>Mechanism Name: Project SOAR</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 575,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 575,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	575,000

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Budget Code Information



<b>Mechanism ID: 18404</b>			
<b>Mechanism Name: Project SOAR</b>			
<b>Prime Partner Name: Population Council</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	150,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	425,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18420</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 18430</b>	<b>Mechanism Name: CDC Namibia</b>
Funding Agency: HHS/CDC	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>



GHP-State	0
-----------	---

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18430		
<b>Mechanism Name:</b>	CDC Namibia		
<b>Prime Partner Name:</b>	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18608</b>	<b>Mechanism Name: Technical Support to PEPFAR Programs in Southern Africa</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Baylor University, College of Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 400,000</b>	<b>Total Mechanism Pipeline: N/A</b>

Approved



<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 400,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	400,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18608</b>			
<b>Mechanism Name: Technical Support to PEPFAR Programs in Southern Africa</b>			
<b>Prime Partner Name: Baylor University, College of Medicine</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	200,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 18611</b>	<b>Mechanism Name: Clinical and Laboratory Standards Institute (CLSI)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes





Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 223,089</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 223,089</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	223,089

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18611		
<b>Mechanism Name:</b>	Clinical and Laboratory Standards Institute (CLSI)		
<b>Prime Partner Name:</b>	Clinical and Laboratory Standards Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	223,089	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18612</b>	<b>Mechanism Name: Demographic and Health Surveys Program</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: ICF Macro	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 150,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 150,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	150,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18612		
<b>Mechanism Name:</b>	Demographic and Health Surveys Program		
<b>Prime Partner Name:</b>	ICF Macro		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	150,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18658</b>	<b>TBD: Yes</b>
----------------------------	-----------------

Approved



**REDACTED**



**Agency Information - Costs of Doing Business**  
**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		127,024		127,024	0	127,024
ICASS		244,262		244,262	0	244,262
Institutional Contractors				0	0	0
Management Meetings/Professional Development		77,598		77,598	0	77,598
Non-ICASS Administrative Costs		544,047		544,047	0	544,047
Staff Program Travel		304,917		304,917	0	304,917
USG Staff Salaries and Benefits - Internationally Recruited		1,469,818		1,469,818	0	1,469,818
USG Staff Salaries and Benefits - Locally Recruited		2,102,048		2,102,048	0	2,102,048



<b>Total</b>	<b>0</b>	<b>4,869,714</b>	<b>0</b>	<b>4,869,714</b>	<b>0</b>	<b>4,869,714</b>
--------------	----------	------------------	----------	------------------	----------	------------------

**U.S. Department of Defense**

<b>Agency Cost of Doing Business</b>	<b>GAP</b>	<b>GHP-State</b>	<b>GHP-USAID</b>	<b>Funding Source Total</b>	<b>Applied Pipeline</b>	<b>Total All Funding Sources and Applied Pipeline Amount</b>
Capital Security Cost Sharing		0		0	0	0
Computers/IT Services		0		0	0	0
ICASS		0		0	0	0
Institutional Contractors		0		0	0	0
Management Meetings/Professional Development		0		0	0	0
Non-ICASS Administrative Costs		0		0	0	0
Staff Program Travel		0		0	0	0
USG Staff Salaries and Benefits - Internationally Recruited		0		0	0	0
USG Staff Salaries and Benefits -		0		0	0	0



Locally Recruited						
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		81,175		81,175	0	81,175
Computers/IT Services		60,000		60,000	0	60,000
ICASS		652,000		652,000	0	652,000
Institutional Contractors	0	2,025,146		2,025,146	0	2,025,146
Management Meetings/Professional Development		46,000		46,000	0	46,000
Non-ICASS Administrative Costs		647,738		647,738	0	647,738
Non-ICASS Motor Vehicles		52,000		52,000	0	52,000
Staff Program Travel	0	436,777		436,777	0	436,777
USG Staff Salaries and Benefits -	1,487,500	1,898,744		3,386,244	0	3,386,244



Internationally Recruited						
USG Staff Salaries and Benefits - Locally Recruited	0	1,365,059		1,365,059	0	1,365,059
<b>Total</b>	<b>1,487,500</b>	<b>7,264,639</b>	<b>0</b>	<b>8,752,139</b>	<b>0</b>	<b>8,752,139</b>

**U.S. Department of State**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		0		0	14,000	14,000
ICASS		100,000		100,000	0	100,000
Management Meetings/Professional Development		0		0	53,000	53,000
Non-ICASS Administrative Costs		57,299		57,299	209,821	267,120
Peace Corps Volunteer Costs				0	10,000	10,000
Staff Program Travel				0	51,800	51,800
USG Staff Salaries and Benefits -				0	143,791	143,791



Locally Recruited						
<b>Total</b>	<b>0</b>	<b>157,299</b>	<b>0</b>	<b>157,299</b>	<b>482,412</b>	<b>639,711</b>

**U.S. Peace Corps**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Non-ICASS Administrative Costs		0		0	154,303	154,303
Non-ICASS Motor Vehicles		0		0	1,365	1,365
Peace Corps Volunteer Costs		0		0	653,674	653,674
Staff Program Travel		0		0	58,337	58,337
USG Staff Salaries and Benefits - Locally Recruited		0		0	286,540	286,540
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1,154,219</b>	<b>1,154,219</b>